OBJECTIVE: To determine prevalence, incidence and risk factors for CMH in
a young general population.
DESIGN: A cohort of Danish twins (aged 12-41 years) was prospectively examined using questionnaires in 1994 (n = 29 180) and in 2002 (n = 21 130). Prevalence and incidence of CMH were determined, and risk factors for the condition were assessed using logistic regression.
RESULTS: Lifetime prevalence of CMH was 8.6% in females and 6.9% in males in 1994, and the cumulative incidence among females and males was respectively 10.7% and 8.7% during the study period. Smoking and asthma were risk factors for CMH, with a dose-response effect of tobacco consumption, and smoking Neuronal Signaling inhibitor habits also predicting incidence of CMH.
CONCLUSION: Among the young, CMH is a condition
related to asthma and smoking, with a dose-response relationship with tobacco consumption and a relation between smoking habits and incidence. Female susceptibility to development of CMH was observed, as well as signs of greater susceptibility related to young age.”
“Aim: To analyze the influence of computed tomography (CT)-guided 3D conformal interstitial brachytherapy (3D-IBT) boost for better coverage of target volumes and study the diametric impact to organ at risk in patients with post-surgery recurrent and residual cervical cancer. Material and Methods: Fourteen consecutive patients with recurrent or residual cervical cancer who were treated with interstitial brachytherapy as a boost were included in the study. All patients received 50.4 Gy external radiation (EBRT) to whole pelvis with conformal technique to reduce the dose to bowel. The clinical target volume p38 MAPK inhibitor (CTV) and organs at risk were contoured on CT scan with gold seeds being a surrogate marker of initial tumor extent implanted before commencing treatment. The median dose of prescription
was 10.512 Gy in 3 fractions. Dose volume histogram was calculated to evaluate the dose that covers 100% and 90% of the target volume and dose to the bladder, Liproxstatin-1 rectum and bowel (2 mL, 1 mL volume). Results: The median follow-up was 12 months (range 618). The doses to CTV (D90, D100) ranged from 1141 to 2014 cGy, and 585 to 969 cGy, respectively. The mean cumulative 2-mL rectal, bladder and bowel doses were 66.70, 73.15 and 61.01 Gy, respectively. Rectal toxicity of grade 2 or more had a strong correlation with the dose delivered (Spearman’s correlation, 0.950). The local control rate at one year was 92% with failure seen in one patient only. Conclusion: Conformal EBRT supplemented with 3D-IBT seems to be a practical and appropriate approach to give the most optimal therapeutic benefit with the least side-effects in postoperative recurrent and residual cervical cancer patients.”
“BACKGROUND: Centres in Phases land III of the International Study of Asthma and Allergies in Childhood (ISAAC) programme used the method of consent (passive or active) required by local ethics committees.